The latest news about semaglutide

a { color: #880000 !important; background: #ffeeee !important; } Why is in the news at the moment?

Stories involving

Semaglutide's Broader Health Benefits Revealed

Recent studies indicate that semaglutide, marketed as Ozempic and Wegovy, may significantly reduce mortality rates and slow aging in overweight individuals with cardiovascular disease. The drug shows potential benefits beyond weight loss, including lower death rates from various causes, including COVID-19. These findings were presented at the European Society of Cardiology Conference.

Health Risks of Ozempic and Wegovy

Recent lawsuits highlight serious health complications linked to weight-loss drugs Ozempic and Wegovy. Patients report severe side effects, including gastrointestinal issues and, in some cases, life-threatening conditions. These developments raise concerns about the safety and regulatory oversight of these medications, prompting legal action against their manufacturer, Novo Nordisk.